Third Harmonic Bio Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Third Harmonic Bio, Inc. |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
THRD Q1 2025 10-Q filed. Financials and ops update.
AI Summary
Third Harmonic Bio, Inc. filed its quarterly report for the period ending March 31, 2025. The company's primary focus remains on its pharmaceutical preparations business. Key financial details and operational segments are outlined within the filing, which also references specific stock plans and executive compensation elements.
Why It Matters
This filing provides investors with an update on Third Harmonic Bio's financial health and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial and operational updates.
Key Players & Entities
- Third Harmonic Bio, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date
- Novartis (company) — Mentioned in relation to stock plans
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the first quarter of 2025.
When was this 10-Q filed with the SEC?
The filing date is 20250508.
What is Third Harmonic Bio, Inc.'s Standard Industrial Classification code?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Are there any specific stock plans mentioned in the filing?
Yes, the filing references 'TwoThousandAndTwentyTwoStockOptionAndIncentivePlanMember' and 'RestrictedStockMember'.
What is the business address of Third Harmonic Bio, Inc.?
The business address is 1700 Montgomery Street, Suite 210, San Francisco, CA 94111.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Third Harmonic Bio, Inc..